Trial Profile
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Efmarodocokin alfa (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Genentech
- 20 Nov 2018 Status changed from active, no longer recruiting to completed.
- 13 Jul 2018 Planned End Date changed from 21 Nov 2018 to 23 Nov 2018.
- 13 Jul 2018 Planned primary completion date changed from 21 Nov 2018 to 23 Nov 2018.